1430 US Highway 206
United States - Map
CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. The company markets Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, and central venous catheters used for vascular access in hemodialysis patients. Its product candidate is CRMD004, which is the gel formulation of Neutrolin intended for the treatment of wounds, skin infections, soft tissue infections, and the prevention of catheter exit site infections. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.
|CorMedix, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 2; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Randy D. Milby MBA,
Interim Chief Exec. Officer and Director
|Dr. Antony E. Pfaffle M.D.,
Co-Founder, Vice Chairman, Chief Scientific Officer and Sec.
|Mr. James R. Altland CPA,
Interim Chief Financial Officer and Consultant
|Dr. William J. Vanjonack Ph.D.,
VP of Technical Operations
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|